Abstract:The growth factor receptor-bound protein 2 (Grb2) is an SH2 domain-containing docking module that represents an attractive target for anticancer therapeutic intervention. An impressive number of synthetic Grb2-SH2 domain inhibitors have been identified; however, clinical agents operating by this mechanism are lacking, due in part to the unique requirement of anionic phosphate-mimicking functionality for high SH2 domain-binding affinity or the extended peptide nature of most inhibitors. In the current study, a new binding motif was successfully developed by the incorporation of 3'-substituted tyrosine derivatives into a simplified nonphosphorylated cyclic pentapeptide scaffold (4), which resulted in high affinity Grb2-SH2 inhibitors without any phosphotyrosine or phosphotyrosine mimetics. The new L-amino acid analogues bearing an additional nitro, amino, hydroxy, methoxy or carboxy group at the 3'-position of the phenol ring of tyrosine were prepared in an orthogonally protected form suitable for solid-phase peptide synthesis using Fmoc protocols. The incorporation of these residues into cyclic peptides composed of a five-amino acid sequence motif, Xx(1)-Leu-(3'-substituted-Tyr)-Ac6c-Asn, provided a brand new class of nonphosphorylated Grb2 SH2 domain inhibitors with reduced size, charge and peptidic character. The highest binding affinity was exhibited by the 3'-aminotyrosine (3'-NH2-Tyr)-containing (R)-sulfoxide-cyclized pentapeptide (10b) with an IC50 = 58 nM, the first example with low-nanomolar affinity for a five-amino acid long sequence binding to Grb2-SH2 domain free of any phosphotyrosine or phosphotyrosine mimics. However, the incorporation of 3'-NO2-Tyr, 3'-OH-Tyr or 3'-OCH3-Tyr surrogates in the pentapeptide scaffold is detrimental to Grb2-SH2 binding. These observations were rationalized using molecular modeling. More significantly, the best Grb2-SH2 inhibitor 10b showed excellent activity in inhibiting the growth of erbB2-dependent MDA-MB-453 tumor cell lines with an IC50 value of 19 nM. This study is the first attempt to identify novel nonphosphorylated high affinity Grb2 SH2 inhibitors by the utilization of 3'-substituted tyrosine derivatives, providing a promising new strategy and template for the development of non-pTyr-containing Grb2-SH2 domain antagonists with potent cellular activity, which potentially may find value in chemical therapeutics for erbB2-related cancers.

Potent Grb2-SH2 Domain Antagonists Not Relying on Phosphotyrosine Mimics.

Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.

Discovery of A Novel Nonphosphorylated Pentapeptide Motif Displaying High Affinity for Grb2-Sh2 Domain by the Utilization of 3 '-Substituted Tyrosine Derivatives

Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.

Potentiating Effect of Distant Sites in Non-Phosphorylated Cyclic Peptide Antagonists of the Grb2-SH2 Domain

Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine

A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity.

Novel Nonphosphorylated Peptides With Conserved Sequences Selectively Bind To Grb7 Sh2 Domain With Affinity Comparable To Its Phosphorylated Ligand

Ligand-Based Structural Optimization of Grb2-SH2 Inhibitors: High Affinity, Low Charge and Reduced Peptidic Nature

Global Optimization of Conformational Constraint on Non-Phosphorylated Cyclic Peptide Antagonists of the Grb2-SH2 Domain

Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.

Utilization Of 3 '-Carboxy-Containing Tyrosine Derivatives As A New Class Of Phosphotyrosyl Mimetics In The Preparation Of Novel Non-Phosphorylated Cyclic Peptide Inhibitors Of The Grb2-Sh2 Domain

Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain.

Utilization of A Beta-Aminophosphotyrosyl Mimetic in the Design and Synthesis of Macrocyclic Grb2 Sh2 Domain-Binding Peptides

Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity.

Functional Preference of the Constituent Amino Acid Residues in a Phage-Library-based Nonphosphorylated Inhibitor of the Grb2-SH2 Domain.

Targeted Covalent Inhibition of Grb2-Sos1 Interaction Through Proximity-Induced Conjugation in Breast Cancer Cells.

Inhibition of Angiogenesis by Growth Factor Receptor Bound Protein 2-Src Homology 2 Domain Bound Antagonists

Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Concise and Enantioselective Synthesis of Fmoc-Pmp(Bu<sup>t</sup>)<sub>2</sub>-OH and Design of Potent Pmp-Containing Grb2-SH2 Domain Antagonists